Celgene Corporation (NASDAQ:CELG) announced this morning that it is acquiring Juno Therapeutics Inc (NASDAQ:JUNO) for $9 billion or $87/share (net of the ~10% it …
In reaction to acquisition buzz in the market’s grapevine, Maxim’s Jason McCarthy is out boosting his price target on Juno stock.
Healthcare analysts share thoughts on a potential acquisition of Juno Therapeutics.
Juno Therapeutics Inc (NASDAQ:JUNO) shares gained 9% after the company said it will present updated clinical and preclinical results from the company and …
Juno Therapeutics Inc (NASDAQ:JUNO) unveiled its new headquarters and research facility, located in the heart of South Lake Union in Seattle. The new headquarters brings together Juno’s Seattle employees …
David Nierengarten Re-evaluates JUNO; Upgrades Shares to Outperform
How Has a Deal Between Kite and Gilead Likewise Sent Juno Shares Jumping?
In a research report published Monday, BTIG analyst Dane Leone reiterated a Neutral rating on shares of Juno Therapeutics Inc (NASDAQ:JUNO), after the …
Juno Therapeutics Inc (NASDAQ:JUNO) announced updated data from the TRANSCEND trial of JCAR017 in relapsed and refractory (r/r) aggressive B cell non-Hodgkin lymphoma …
Juno Therapeutics Inc (NASDAQ:JUNO) shares are dropping 7% following the biotech firm’s official termination of their JCAR015 program for the treatment of patients …